ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

Core Insights - ProMIS Neurosciences has completed enrollment for its PRECISE-AD Phase 1b trial, with 144 patients enrolled, exceeding the target of 128, indicating strong interest in PMN310's therapeutic potential [3][8] - The company reported a net loss of $39.7 million for the year ended December 31, 2025, with cash reserves of $6.1 million, reflecting its investment in advancing the PRECISE-AD trial [12][24] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported to date, and it is designed to minimize treatment-related side effects, particularly Amyloid-Related Imaging Abnormalities (ARIA) [4][15] Clinical Development - The PRECISE-AD trial is expected to complete six-month assessments in Q2 2026, with a blinded interim analysis anticipated in early Q3 2026 and top-line data expected in early 2027 [1][9] - PMN310 has been granted Fast Track Designation by the FDA, which may facilitate its development and regulatory engagement [7][15] - The company is also developing a subcutaneous formulation of PMN310 to improve patient experience and strengthen its competitive profile [6][13] Financial Overview - The company closed a financing round in early 2026, raising up to $175 million, which includes $75 million upfront and $100 million tied to future warrant exercises, providing a cash runway through 2027 [6][12] - Research and development expenses for 2025 were $33.4 million, significantly higher than the $10.6 million in 2024, primarily due to costs associated with the PRECISE-AD trial [12][24] - General and administrative expenses increased to $6.8 million in 2025 from $6.2 million in 2024, driven by a moderate increase in employee headcount [12][24] Pipeline and Future Directions - PMN267 and PMN442 are other key pipeline candidates targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), respectively, with PMN267 showing selectivity for pathogenic TDP-43 and PMN442 targeting alpha-synuclein [13][14] - The company is monitoring developments in preclinical and asymptomatic Alzheimer's disease trials, considering potential expansion into these areas based on PMN310's safety profile [8]